Another major study finds cannabis users are thinner and have better cardiometabolic levels than controls. This may surprise many as activation of the endocannabinoid system, which is a function cannabis use, is associated in much of the research by increased feeding (the munchies) and poor cardiometabolic indicators, such as bad lipid levels. Indeed, until shown in 2006 to have negative, even dangerous psychological effects, cannabinoid receptor antagonists which essential have the opposite effects of cannabis were anticipated to be powerful weight loss drugs with positive cardiometabolic effects, mentioned in an earlier post here. The FDA quashed introduction of these drugs, e.g. rimanobant when they were found to be powerfully depressing. It makes sense; cannabis provides mild feelings of well-being and enjoyment, the antagonist, opposite drug seems to provoke the opposite emotion, depression.
The new study, reported in The American Journal of Medicine, demonstrates a positive impact of marijuana use on key cardiometabolic indicators. Titled The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults, the study shows all these key parameters are healthier in marijuana consumers. The study was written up in The Atlantic by Lindsey Abrams and reveals that the cannabis users were healthier in indices crucial to the health of Americans and billions of other world wide with less obesity, better glucose and insulin levels and less insulin resistance. As diabetes is a major killer and disabler, the fact that cannabis use might help is astounding.
With the USA teetering on the edge of a health care cost crisis, due in good part to obesity and diabetes, one might think that the American medical care system would be eager to explore and research cannabis with controlled studies in the prevention and treatment of these conditions. But this will not take place as the DEA has a lock on all research on marijuana and allows none.